BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 11076265)

  • 1. [Polycythemia vera: current status of therapy].
    Lengfelder E; Hehlmann R
    Dtsch Med Wochenschr; 2000 Oct; 125(41):1243-7. PubMed ID: 11076265
    [No Abstract]   [Full Text] [Related]  

  • 2. [Efficacious treatment of a fatal blood disease: polycythemia vera].
    Sánchez Fayos J; Román Barbero A; Nevado Reviriego I
    Sangre (Barc); 1997 Jun; 42(3):215-8. PubMed ID: 9381264
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
    Sever M; Newberry KJ; Verstovsek S
    Leuk Lymphoma; 2014 Dec; 55(12):2685-90. PubMed ID: 24524340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic options for essential thrombocythemia and polycythemia vera.
    Solberg LA
    Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vaquez disease. Diagnosis, course, treatment].
    Bauters F
    Rev Prat; 1998 Sep; 48(13):1483-9. PubMed ID: 10050634
    [No Abstract]   [Full Text] [Related]  

  • 7. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
    Barbui T
    Semin Hematol; 2004 Apr; 41(2 Suppl 3):15-7. PubMed ID: 15190518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modern treatment strategies in polycythemia vera.
    Gilbert HS
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):26-9. PubMed ID: 12682879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
    Boivin P
    Nouv Rev Fr Hematol (1978); 1993; 35(5):491-8. PubMed ID: 8295823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.
    Kiladjian JJ; Gardin C; Renoux M; Bruno F; Bernard JF
    Hematol J; 2003; 4(3):198-207. PubMed ID: 12764352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of polycythaemia vera and essential thrombocythaemia.
    Tefferi A; Silverstein MN
    Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of the myeloproliferative disorders : distinguishing data from dogma.
    Green AR; Vassiliou GS; Curtin N; Campbell PJ
    Hematol J; 2004; 5 Suppl 3():S126-32. PubMed ID: 15190294
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
    Michiels JJ; Barbui T; Finazzi G; Fuchtman SM; Kutti J; Rain JD; Silver RT; Tefferi A; Thiele J
    Leuk Lymphoma; 2000 Jan; 36(3-4):239-53. PubMed ID: 10674896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-based management of polycythemia vera.
    Barbui T; Finazzi G
    Best Pract Res Clin Haematol; 2006; 19(3):483-93. PubMed ID: 16781485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age].
    Najean Y; Rain JD; Lejeune F; Echard M; Fermand JP; Gruyer P; Brahimi S
    Ann Med Interne (Paris); 1998 Mar; 149(2):94-100. PubMed ID: 11490531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs in essential thrombocythemia and polycythemia vera.
    Tefferi A; Elliott MA; Solberg LA; Silverstein MN
    Blood Rev; 1997 Mar; 11(1):1-7. PubMed ID: 9218101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
    Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Essential thrombocythemia: conventional therapy].
    Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
    Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
    [No Abstract]   [Full Text] [Related]  

  • 20. New Therapeutic Approaches in Polycythemia Vera.
    Falchi L; Newberry KJ; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S27-33. PubMed ID: 26297275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.